NeuroSense Therapeutics Ltd. (NRSN) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Biotecnología industria. La empresa tiene su sede en Herzliya, Israel. El CEO actual es Alon Ben-Noon.
NRSN tiene fecha de IPO 2021-12-09, 17 empleados a tiempo completo, cotiza en el NASDAQ Capital Marke, una capitalización de mercado de $18.01M.
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of treatment for patients suffering from debilitating neurodegenerative diseases. Its lead product, PrimeC, is a novel oral formulation that has completed Phase IIa clinical trials for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.
